MUFG Americas Holdings Corp lessened its stake in Becton Dickinson (NYSE:BDX) by 9.8% in the first quarter, HoldingsChannel.com reports. The firm owned 16,135 shares of the medical instruments supplier’s stock after selling 1,754 shares during the period. MUFG Americas Holdings Corp’s holdings in Becton Dickinson were worth $3,496,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently bought and sold shares of the business. Legacy Advisors LLC grew its position in shares of Becton Dickinson by 7,000.0% during the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 490 shares during the period. Amica Retiree Medical Trust grew its position in shares of Becton Dickinson by 325.0% during the 4th quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after acquiring an additional 390 shares during the period. Almanack Investment Partners LLC. bought a new stake in shares of Becton Dickinson during the 4th quarter valued at $109,000. FTB Advisors Inc. grew its position in shares of Becton Dickinson by 114.2% during the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 290 shares during the period. Finally, Advisors Preferred LLC bought a new stake in shares of Becton Dickinson during the 4th quarter valued at $126,000. 84.02% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Becton Dickinson from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Citigroup raised shares of Becton Dickinson from a “neutral” rating to a “buy” rating and upped their target price for the stock from $237.00 to $251.00 in a report on Tuesday, April 10th. Zacks Investment Research downgraded shares of Becton Dickinson from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. BMO Capital Markets initiated coverage on shares of Becton Dickinson in a report on Monday, March 5th. They issued a “market perform” rating and a $249.00 target price for the company. Finally, Morgan Stanley upped their target price on shares of Becton Dickinson from $245.00 to $250.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson presently has a consensus rating of “Buy” and a consensus target price of $241.19.
Shares of BDX stock opened at $225.24 on Monday. The firm has a market capitalization of $60.18 billion, a price-to-earnings ratio of 23.76, a P/E/G ratio of 1.57 and a beta of 1.15. Becton Dickinson has a 52 week low of $180.44 and a 52 week high of $248.39. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.12 and a current ratio of 1.70.
Becton Dickinson (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 EPS for the quarter, topping the consensus estimate of $2.63 by $0.02. The business had revenue of $4.22 billion for the quarter, compared to analysts’ expectations of $4.12 billion. Becton Dickinson had a negative net margin of 0.46% and a positive return on equity of 14.27%. The business’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.30 EPS. equities analysts expect that Becton Dickinson will post 10.99 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 8th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.33%. The ex-dividend date of this dividend is Thursday, June 7th. Becton Dickinson’s payout ratio is currently 31.65%.
Becton Dickinson Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson (NYSE:BDX).
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.